Kosloski, Matthew P.
Wang, Haoyu
Pugatch, David
Mensa, Federico J.
Gane, Edward
Lawitz, Eric
Marbury, Thomas C.
Preston, Richard A.
Kort, Jens
Liu, Wei
Funding for this research was provided by:
AbbVie (n/a)
Article History
Received: 8 August 2018
Accepted: 3 October 2018
First Online: 19 October 2018
Compliance with ethical standards
:
: Matthew Kosloski, Haoyu Wang, David Pugatch, Federico Mensa, Jens Kort, and Wei Liu are employees of AbbVie, Inc. and may hold stock or stock options. Edward Gane is faculty at University of Auckland, Auckland, New Zealand, is a consultant/Advisory Board member for AbbVie, Gilead, Janssen, and Merck/MSD, and is a speaker for AbbVie and Gilead. Eric Lawitz is an employee of Texas Liver Institute, University of Texas Health San Antonio, San Antonio, TX, USA and is a speaker for AbbVie, Gilead, and Merck. Dr. Lawitz has received research/grant support from AbbVie, Boehringer Ingelheim, BMS, Gilead Sciences, GSK, Intercept Pharmaceuticals, Janssen, Merck, and Novartis, and he serves as an advisor for AbbVie, Achillion, BioCryst, Biotica, Enanta, Janssen, Merck, and Novartis. Thomas C. Marbury is an employee and equity owner of Orlando Clinical Research Center, Orlando, FL, USA and has no other conflicts of interest to disclose. Richard A. Preston is faculty at the Miller School of Medicine, University of Miami, Miami, FL, USA and he has received grant/research support from AbbVie, Celerion, Chiasma, Celgene, Conatus, Forest, Pfizer, Parexel, PPD, Takeda, Novartis, Exelixis, Idenix, PPD, Akros, ApoPharma, Merck, Fujifi lm, Reata, and Watson.
: The study was conducted in accordance with International Conference for Harmonization Good Clinical Practice guidelines and ethical principles that have their origin in the Declaration of Helsinki.
: Written informed consent was obtained from each subject before any study-related procedures were performed.